KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unitedhealth (UNH) Share-based Compensation (2016 - 2025)

Unitedhealth (UNH) has disclosed Share-based Compensation for 17 consecutive years, with $176.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 5.88% to $176.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $971.0 million, a 4.62% decrease, with the full-year FY2025 number at $971.0 million, down 4.62% from a year prior.
  • Share-based Compensation was $176.0 million for Q4 2025 at Unitedhealth, down from $223.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $375.0 million in Q1 2025 to a low of $165.0 million in Q3 2021.
  • A 5-year average of $240.2 million and a median of $223.0 million in 2025 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 44.44% in 2023; the steepest drop was 16.8% in 2023.
  • Unitedhealth's Share-based Compensation stood at $165.0 million in 2021, then soared by 51.52% to $250.0 million in 2022, then dropped by 16.8% to $208.0 million in 2023, then fell by 10.1% to $187.0 million in 2024, then fell by 5.88% to $176.0 million in 2025.
  • Per Business Quant, the three most recent readings for UNH's Share-based Compensation are $176.0 million (Q4 2025), $223.0 million (Q3 2025), and $197.0 million (Q2 2025).